2 Medications for Type 2 Diabetes
Review how commonly used non-insulin medicines for type 2 diabetes lower glucose, their important safety considerations, and how heart, kidney, weight, and patient-specific factors shape treatment choices.
Choosing treatment
Non-insulin medicines for type 2 diabetes include oral and injectable treatments that lower glucose through different mechanisms. They also differ in effects on weight, risk, and heart or kidney outcomes.
Treatment is individualized according to glucose goals, heart and kidney conditions, weight goals, risks of adverse effects, cost, and patient preferences. Medication decisions and changes should be made with a qualified clinician.
: action and precautions
primarily lowers glucose by reducing hepatic glucose production and improving insulin sensitivity. Gastrointestinal effects, including nausea or diarrhea, are common, especially when starting treatment. Taking it with food and increasing the dose gradually may improve tolerance.
is contraindicated when eGFR is below . Long-term use can contribute to vitamin B12 deficiency, so monitoring may be appropriate.
and low blood glucose
stimulate insulin secretion from the pancreas. This can cause , particularly when meals are missed or delayed; these medicines may also cause weight gain.
Patients should learn to recognize symptoms of low blood glucose and follow their care team's plan for treating it. When another glucose-lowering medicine is added, the need for a sulfonylurea should be reassessed.
: effects and precautions
reduce glucose reabsorption in the kidneys, increasing glucose excretion in urine. Important risks include genital fungal infections, dehydration or low blood pressure, and, rarely, .
Ketoacidosis can occur even without markedly elevated blood glucose. Nausea, vomiting, abdominal pain, or difficulty breathing may be symptoms requiring prompt assessment.
Patients should discuss illness, prolonged fasting, and planned surgery with their care team. Empagliflozin labeling advises withholding it for at least three days before surgery when possible.
GLP-1 medicines and
enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying. They often reduce appetite and body weight. Nausea, vomiting, diarrhea, and constipation are common adverse effects.
is contraindicated in people with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients should also tell clinicians about planned procedures that require anesthesia or deep sedation.
Taking oral
Oral should be taken in the morning on an empty stomach with a small amount of plain water. Swallow the tablet whole, then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Following these instructions helps ensure proper absorption.
and combinations
prolong incretin activity. When used alone, they are generally weight-neutral and have a low risk of .
Combining a DPP-4 inhibitor with a GLP-1 receptor agonist, or with the dual GIP/GLP-1 medicine tirzepatide, is generally not recommended because it does not provide additional glucose lowering beyond the GLP-1-based treatment.
and fluid retention
improves insulin sensitivity but can cause fluid retention, edema, and weight gain, and can worsen heart failure. A history or symptoms of heart failure call for careful clinical assessment before use. New or worsening shortness of breath or swelling should be reported promptly.
Considering heart and kidney health
For many people with type 2 diabetes and heart failure or , an SGLT2 inhibitor with demonstrated benefit is recommended for heart and kidney protection, even when glucose lowering is not the only treatment goal. A GLP-1 receptor agonist with demonstrated benefit may also be appropriate for some patients.
Medication selection should not depend only on A1C. It also depends on the person's health conditions, kidney function, medication risks, and preferences.
Comparing safety considerations
The medicine classes differ in both how they lower glucose and the risks that require attention. Important distinctions include with ; genital infections and ketoacidosis precautions with ; gastrointestinal effects and specific contraindications with GLP-1-based medicines; and fluid retention with .
Counseling should match the medicine and the individual's risks. The choice of treatment may also reflect weight goals, heart and kidney conditions, cost, and patient preferences.